Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.

Michels, Renée Else; De Francesco, Maria; Mahajan, Koshu; Hengstman, Gerald J D; Schiffers, Krijn M H; Budhia, Sangeeta; Harty, Gerard; Krol, Marieke

Michels, Renée Else; De Francesco, Maria; Mahajan, Koshu; Hengstman, Gerald J D; Schiffers, Krijn M H; Budhia, Sangeeta; Harty, Gerard; Krol, Marieke.

Afiliación

Michels RE; IQVIA, Real World Evidence Solutions, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands.
De Francesco M; IQVIA, Real World Insights, Da Vincilaan 7, 1930, Zaventem, Belgium.
Mahajan K; IQVIA, Real World Insights, Gurgaon, India.
Hengstman GJD; Department of Neurology, Catharina Hospital, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands.
Schiffers KMH; Merck B.V., Tupolevlaan 41-61, 1119 NW, Schiphol-Rijk, The Netherlands.
Budhia S; PAREXEL International, PAREXEL Access Consulting, London, UK.
Harty G; EMD Serono, a business of Merck KGaA, Boston, MA, USA.
Krol M; IQVIA, Real World Evidence Solutions, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands. Marieke.Krol@iqvia.com.

Appl Health Econ Health Policy ; 18(1): 141, 2020 Feb.

Article en En | MEDLINE | ID: mdl-31939112

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation Idioma: En Revista: Appl Health Econ Health Policy Asunto de la revista: SAUDE PUBLICA / SERVICOS DE SAUDE Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google